蛋白质糖基化修饰在肝细胞癌中的功能和临床意义

doi:10.11904/j.issn.1002-3070.2026.01.008

Abstract

Abstract: Hepatocellular carcinoma(HCC)is one of the most prevalent and poorly prognostic malignant tumors globally.Protein glycosylation,as one of the most abundant and diverse forms of post-translational modification(PTM),plays a crucial regulatory role in the occurrence and progression of HCC.This article systematically reviews the different types,regulatory mechanisms and biological functions of glycosylation modifications,and elucidates the mechanisms by which abnormal glycosylation affects the malignant progression of HCC through remodeling cell adhesion,promoting angiogenesis,regulating metabolic reprogramming,and mediating immune escape.Furthermore,this article discusses the translational potential of glycosylation in the diagnosis,prognostic assessment,and targeted therapy of HCC.Finally,this article provides an outlook on future directions in glycosylation,emphasizing its significant value in advancing precision medicine for HCC.

Key words: hepatocellular carcinoma, glycosylation, tumor microenvironment, immune evasion, targeted therapy

CLC Number:

R735.7

QUAN Xinzhu, PAN Yufei, WANG Hongyang, DONG Liwei. Functional and clinical significance of protein glycosylation modification in hepatocellular[J]. Journal of Practical Oncology, 2026, 40(1): 56-63.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2026.01.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2026/V40/I1/56

References

1 辛鑫,熊文婧,张春暖,等.乳酸化修饰:癌症治疗中的新兴靶点[J].实用肿瘤学杂志,2025,39(5):433-436.
2 Qin J,Zhu W,Yang Z,et al.Post-translational modifications in hepatocellular carcinoma:mechanisms and therapeutic potential[J].Med Oncol,2025,42(11):524.
3 He M,Zhou X,and Wang X.Glycosylation:mechanisms,biological functions and clinical implications[J].Signal Transduct Target Ther,2024,9(1):194.
4 李薇,刘天华,张舒,等.肿瘤转移相关糖基转移酶表达调控研究进展[J].中国临床医学,2016,23(2):233-236.
5 Esmail S,Manolson MF.Advances in understanding N-glycosylation structure,function,and regulation in health and disease[J].Eur J Cell Biol,2021,100(7-8):151186.
6 李佳丽,宋泽庆,刘刚.蛋白质糖基化与疾病关系的研究进展[J].海南医学,2023,34(4):589-592.
7 Fu B,Chen J,Liu X,et al.Large-scale serum N-glycomics tracks N-glycosylation dynamics in hepatocellular carcinoma progression and enables early diagnosis[J].Nat Commun,2026.
8 Magalhães A,Duarte HO,and Reis CA.The role of O-glycosylation in human disease[J].Mol Aspects Med,2021,79:100964.
9 Zhou P,Chang WY,Gong DA,et al.High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-glcnacylation via microbiota-derived acetate[J].Cell Metab,2023,35(11):1961-1975.e1966.
10 Lin MC,Chuang YT,Wu HY,et al.Targeting tumor O-glycosylation modulates cancer-immune-cell crosstalk and enhances anti-PD-1 immunotherapy in head and neck cancer[J].Mol Oncol,2024,18(2):350-368.
11 Lundgren JG,Flynn MG,and List K.GPI-anchored serine proteases:essential roles in development,homeostasis,and disease[J].Biol Chem,2025,406(1-2):1-28.
12 Yang D,Han F,Cai J,et al.N-glycosylation by N-acetylglucosaminyltransferase IVa enhances the interaction of integrin β1 with vimentin and promotes hepatocellular carcinoma cell motility[J].Biochim Biophys Acta Mol Cell Res,2023,1870(7):119513.
13 Cui J,Huang W,Wu B,et al.N-glycosylation by N-acetylglucosaminyltransferase V enhances the interaction of CD147/basigin with integrin β1 and promotes HCC metastasis[J].J Pathol,2018,245(1):41-52.
14 Chen PD,Liao YY,Cheng YC,et al.Decreased B4GALT1 promotes hepatocellular carcinoma cell invasiveness by regulating the laminin-integrin pathway[J].Oncogenesis,2023,12(1):49.
15 Hu M,Zhang R,Yang J,et al.The role of N-glycosylation modification in the pathogenesis of liver cancer[J].Cell Death Dis,2023,14(3):222.
16 Leung Z,Ko FCF,Tey SK,et al.Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells[J].J Exp Clin Cancer Res,2019,38(1):423.
17 Song M,Pan Q,Yang J,et al.Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma[J].Br J Cancer,2020,123(10):1521-1534.
18 Li H,Wu K,Tao K,et al.Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma[J].Hepatology,2012,56(4):1342-1351.
19 Fujita K,Iwama H,Sakamoto T,et al.Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo[J].Int J Oncol,2015,46(6):2419-2430.
20 Jiao J,Jiao D,Yang F,et al.Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma[J].Aging(Albany NY),2022,14(4):1879-1890.
21 Sideras K,Biermann K,Verheij J,et al.PD-L1,galectin-9 and CD8(+)tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma[J].Oncoimmunology,2017,6(2):e1273309.
22 Chen S,Pu J,Bai J,et al.EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis[J].J Exp Clin Cancer Res,2018,37(1):3.
23 Sideras K,de Man RA,Harrington SM,et al.Circulating levels of PD-L1 and galectin-9 are associated with patient survival in surgically treated hepatocellular carcinoma independent of their intra-tumoral expression levels[J].Sci Rep,2019,9(1):10677.
24 Lee TA,Tsai EY,Liu SH,et al.Regulation of PD-L1 glycosylation and advances in cancer immunotherapy[J].Cancer Lett,2025,612:217498.
25 Duan Z,Shi R,Gao B,et al.N-linked glycosylation of PD-L1/PD-1:an emerging target for cancer diagnosis and treatment[J].J Transl Med,2024,22(1):705.
26 Mao Z,Mu J,Gao Z,et al.Biological functions and potential therapeutic significance of O-glcnacylation in hepatic cellular stress and liver diseases[J].Cells,2024,13(10):805.
27 Zhu Q,Wang H,Chai S,et al.O-glcnacylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation[J].Proc Natl Acad Sci U S A,2023,120(13):e2216796120.
28 Xiao R,Tian Y,Zhang J,et al.Increased siglec-9/siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy[J].J Hepatol,2024,80(5):792-804.
29 Radovani B,Gudelj I.N-glycosylation and inflammation;the not-so-sweet relation[J].Front Immunol,2022,13:893365.
30 Islam M,Arlian BM,Pfrengle F,et al.Suppressing immune responses using siglec ligand-decorated anti-receptor antibodies[J].J Am Chem Soc,2022,144(21):9302-9311.
31 Altevogt P,Sammar M,Hüser L,et al.Novel insights into the function of CD24:a driving force in cancer[J].Int J Cancer,2021,148(3):546-559.
32 Zhang Y,He B,Zou P,et al.Targeted release of a bispecific fusion protein SIRPα/siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors[J].J Immunother Cancer,2025,13(4).
33 Barkal AA,Brewer RE,Markovic M,et al.CD24 signalling through macrophage siglec-10 is a target for cancer immunotherapy[J].Nature,2019,572(7769):392-396.
34 Jiang S,Li H,Zhang L,et al.Generic diagramming platform(GDP):a comprehensive database of high-quality biomedical graphics[J].Nucleic Acids Res,2025,53(D1):D1670-d1676.
35 Lin Y,Lubman DM.The role of N-glycosylation in cancer[J].Acta Pharm Sin B,2024,14(3):1098-1110.
36 Schepers EJ,Glaser K,Zwolshen HM,et al.Structural and functional impact of posttranslational modification of glypican-3 on liver carcinogenesis[J].Cancer Res,2023,83(12):1933-1940.
37 Man XB,Tang L,Zhang BH,et al.Upregulation of glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers[J].Liver Int,2005,25(5):962-966.
38 Zhang Y,Li J,Huang Y,et al.Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1[J].Theranostics,2023,13(2):578-595.
39 Wang M,Zhang Z,Chen M,et al.FDW028,a novel FUT8 inhibitor,impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer[J].Cell Death Dis,2023,14(8):495.
40 Shi D,Shi Y,Kaseb AO,et al.Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma:results of phase I trials[J].Clin Cancer Res,2020,26(15):3979-3989.
41 Dou WT,Guo C,Zhu L,et al.Targeted near-infrared fluorescence imaging of liver cancer using dual-peptide-functionalized albumin particles[J].Chem Biomed Imaging,2024,2(1):47-55.
42 Li CW,Lim SO,Chung EM,et al.Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1[J].Cancer Cell,2018,33(2):187-201.e110.
43 Lee HH,Wang YN,Xia W,et al.Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy[J].Cancer Cell,2019,36(2):168-178.e164.
44 Posey AD Jr,Schwab RD,Boesteanu AC,et al.Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma[J].Immunity,2016,44(6):1444-1454.
45 Yankelevich M,Thakur A,Modak S,et al.Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells[J].J Immunother Cancer,2024,12(3):e008744.

[1]	ZHAO Fengjuan, NONG Xiaolian, HUANG Shihuan, LI Fanrong, LU Feichen, YOU Xuemei. The effect of problem-solving therapy on depression,quality of life and immunotherapy outcomes in patients with advanced hepatocellular carcinoma:a randomized controlled trial [J]. Journal of Practical Oncology, 2026, 40(1): 30-40.
[2]	CAI Yihao, ZHAO Junhao, ZHAO Jinlu, LIU Ming. Research progress on the role of SLC1A4 in different malignant tumors [J]. Journal of Practical Oncology, 2026, 40(1): 69-74.
[3]	ZHAO Zhilong, HOU Junming. Research progress on the mechanism and therapeutic targets of extracellular matrix in pancreatic cancer [J]. Journal of Practical Oncology, 2025, 39(6): 535-541.
[4]	CAI Yiqing, DAI Enyong. Recent progress on molecular targeted therapy for gastric cancer [J]. Journal of Practical Oncology, 2025, 39(6): 542-550.
[5]	XIN Xin, XIONG Wenjing, ZHANG Chunnuan, LI Xiaojing, GAO Xue, ZHANG Yue. Lactylation modification:an emerging target in cancer therapy [J]. Journal of Practical Oncology, 2025, 39(5): 433-436.
[6]	LI Dongsheng, LI Zehao, CHEN Yonggang. Application of DNA methylation risk scoring model for ferroptosis related genes in the prognosis and immune feature assessment of colon cancer [J]. Journal of Practical Oncology, 2025, 39(3): 224-234.
[7]	YE Qianni, LI Juan, WANG Falin, LIU Jiaren. Research progress on the role of phytochemicals in tumor microenvironment [J]. Journal of Practical Oncology, 2025, 39(3): 245-250.
[8]	ZHU Lei, HAO Dandan. Research progress on non-coding RNAs in the regulation of ferroptosis mediated sorafenib resistance in hepatocellular carcinoma [J]. Journal of Practical Oncology, 2025, 39(3): 256-261.
[9]	ZHANG Kangjun, FANG Taishi, CEN Fulan, YAN Xu, CHEN Qijun, MA Nan. circ_0008043 promotes glycolysis of hepatocellular carcinoma and the development of hepatocellular carcinoma through miR-198/SLC2A1 axis [J]. Journal of Practical Oncology, 2024, 38(6): 388-401.
[10]	GUAN Yongyu, NIE Hao, ZHANG Chong. Research progress of hepatocellular carcinoma mouse models [J]. Journal of Practical Oncology, 2024, 38(5): 342-348.
[11]	SHAO Yuming, ZHU Kunbing, ZHANG Jie. Research progress of SP/NK-1R system in breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 268-272.
[12]	Breast Oncology Group of Heilongjiang Medical Association. Expert consensus on clinicopathological diagnosis of breast cancer with low expression of HER2 in Heilongjiang province(2024 edition) [J]. Journal of Practical Oncology, 2024, 38(2): 71-78.
[13]	WU Dongyang, CAI Qingshan, LIU Dong, ZUO Ganggang, LI Shudong, LIU Liyou, ZHENG Jianxing. The effects and mechanism of long non-coding RNA CASC15 on proliferation,invasion and migration of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2024, 38(1): 18-29.
[14]	PANG Wu, CHEN Lijiang, ZHU Yu, WU Yakun, ZHANG Wei. The expression of serum miRNA-24 and miRNA-509 in patients with hepatocellular carcinoma and their correlation with prognosis [J]. Journal of Practical Oncology, 2023, 37(5): 411-415.
[15]	FAN Tingting, DING Danni, ZHAO Zixue, YU Yang, HAN Fengjuan. Fatty acid metabolism and ovarian cancer [J]. Journal of Practical Oncology, 2023, 37(5): 429-433.

Functional and clinical significance of protein glycosylation modification in hepatocellular

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments